← Leaderboards
Michael Rutledge Debaun
Vanderbilt University Medical Center
$40,846,229
Attributed
$61,291,177
Total exposure
22
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$59,724,177 · 21
FDA$1,567,000 · 1
By mechanism
U01$35,495,910 · 4
R01$20,668,058 · 5
OT3$1,524,235 · 1
K12$1,289,230 · 1
R38$757,522 · 1
R34$738,430 · 1
Top collaborators
- Shehu Umar Abdullahi7 shared
- Muktar Hassan Aliyu7 shared
- Clinton H. Joiner6 shared
- Lori Chaffin Jordan6 shared
- Solomon Fiifi Ofori-Acquah6 shared
- Courtney D Fitzhugh5 shared
- Debra L Friedman5 shared
- Robert C Strunk5 shared
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Shehu Umar Abdullahi$872,336
- Courtney D Fitzhugh$1,016,311
- Debra L Friedman$19,684,821
- Nafiu Hussain$294,915
- Mustapha Shu'aibu Hikima$220,757
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
- Robert J Adams · Medical College Of Georgia (Mcg)$18,246,639
Research focus
Sickle Cell AnemiaChildUnited States National Institutes Of HealthPainChildhoodIncidenceMorbidity - Disease RatePreventFundingEnrollmentPositioning AttributeAcute Chest SyndromeMeasurementStrokeParticipantFollow-UpScientistLungCohortClinical ResearchBlood TransfusionChronicStroke PreventionResearch Personnel
Grant awards (73)
Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease$841,945
U01 · FY2025 · HL · contact PI
Clonal hematopoiesis and inherited genetic variation in sickle cell disease$779,601
R01 · FY2025 · HL
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease$410,522
K12 · FY2025 · HD
Vanderbilt Stimulating Access to Research in Residency (V-StARR)$378,761
R38 · FY2025 · HL
Stroke Prevention in Nigeria: SPRING 2$369,257
U01 · FY2025 · NS · contact PI
Stroke Prevention in Nigeria: SPRING 2$296,633
U01 · FY2025 · NS · contact PI
American Pediatric Society: Building the Evidence Base to Improve Pediatric Care for Youth in Custody Conference$10,000
R13 · FY2025 · HD
Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease$827,619
U01 · FY2024 · HL · contact PI
Clonal hematopoiesis and inherited genetic variation in sickle cell disease$764,009
R01 · FY2024 · HL
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease$438,716
K12 · FY2024 · HD · contact PI
Vanderbilt Stimulating Access to Research in Residency (V-StARR)$378,761
R38 · FY2024 · HL
Stroke Prevention in Nigeria: SPRING 2$116,949
U01 · FY2024 · NS · contact PI
Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease$849,699
U01 · FY2023 · HL · contact PI
Clonal hematopoiesis and inherited genetic variation in sickle cell disease$817,595
R01 · FY2023 · HL
Stroke Prevention in Nigeria: SPRING 2$617,580
U01 · FY2023 · NS · contact PI
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease$439,992
K12 · FY2023 · HD · contact PI
Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease$854,865
U01 · FY2022 · HL · contact PI
Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease$691,115
U01 · FY2021 · HL · contact PI
Management of severe acute malnutrition in children with sickle cell disease greater than 5 years of age living in northern Nigeria$219,313
R21 · FY2020 · HD · contact PI
Primary prevention of stroke in children with SCD in Sub-Saharan Africa II$1,022,211
R01 · FY2019 · NS · contact PI
Management of severe acute malnutrition in children with sickle cell disease greater than 5 years of age living in northern Nigeria$204,913
R21 · FY2019 · HD · contact PI
Cure Sickle Cell Initiative Data Coordinating Center$1,524,235
OT3 · FY2018 · HL · contact PI
Primary prevention of stroke in children with SCD in Sub-Saharan Africa II$1,018,471
R01 · FY2018 · NS · contact PI
Cellular and Molecular Mechanisms of Acute Lung Injury in Sickle Cell Disease$1,909,806
U01 · FY2017 · HL
Primary prevention of stroke in children with SCD in Sub-Saharan Africa II$1,104,445
R01 · FY2017 · NS · contact PI
Cellular and Molecular Mechanisms of Acute Lung Injury in Sickle Cell Disease$1,909,806
U01 · FY2016 · HL
Primary prevention of stroke in children with SCD in Sub-Saharan Africa II$1,150,318
R01 · FY2016 · NS · contact PI
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia$632,580
R01 · FY2016 · FD · contact PI
Cellular and Molecular Mechanisms of Acute Lung Injury in Sickle Cell Disease$1,881,158
U01 · FY2015 · HL
Primary prevention of stroke in children with SCD in Sub-Saharan Africa II$1,057,951
R01 · FY2015 · NS · contact PI
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia$280,832
R01 · FY2015 · FD · contact PI
Cellular and Molecular Mechanisms of Acute Lung Injury in Sickle Cell Disease$50,298
U01 · FY2015 · HL
Cellular and Molecular Mechanisms of Acute Lung Injury in Sickle Cell Disease$1,729,411
U01 · FY2014 · HL
Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children$371,888
R34 · FY2014 · HL
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia$256,993
R01 · FY2014 · FD · contact PI
Cellular and Molecular Mechanisms of Acute Lung Injury in Sickle Cell Disease$1,897,529
U01 · FY2013 · HL
Asthma and Nocturnal Hypoxemia in Sickle Cell Anemia II$601,585
R01 · FY2013 · HL · contact PI
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia$396,595
R01 · FY2013 · FD · contact PI
Primary Prevention of Strokes in Nigerian Children with Sickle Cell Disease$134,855
R21 · FY2013 · NS · contact PI
Asthma and Nocturnal Hypoxemia in Sickle Cell Anemia II$20,887
R01 · FY2013 · HL · contact PI
Asthma and Nocturnal Hypoxemia in Sickle Cell Anemia II$681,183
R01 · FY2012 · HL · contact PI
Primary Prevention of Strokes in Nigerian Children with Sickle Cell Disease$146,744
R21 · FY2012 · NS · contact PI
Asthma and Nocturnal Hypoxemia in Sickle Cell Anemia II$677,925
R01 · FY2011 · HL · contact PI
Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children$366,542
R34 · FY2011 · HL
Silent Cerebral Infarct Multi-Center Clinical Trial$4,510,212
U01 · FY2010 · NS · contact PI
Asthma and Nocturnal Hypoxemia in Sickle Cell Anemia II$747,716
R01 · FY2010 · HL · contact PI
Silent Cerebral Infarct Multi-Center Clinical Trial$152,000
U01 · FY2010 · NS · contact PI
Silent Cerebral Infarct Multi-Center Clinical Trial$1,571,662
U01 · FY2009 · NS · contact PI
Silent Cerebral Infarct Multi-Center Clinical Trial$1,571,661
U01 · FY2009 · NS · contact PI
2009 Clinical Research Training Institute Summer Workshop$42,500
R13 · FY2009 · HL · contact PI
Silent Cerebral Infarct Multi-Center Clinical Trial$3,509,378
U01 · FY2008 · NS · contact PI
Asthma and Nocturnal Hypoxemia in Sickle Cell Anemia$1,841,516
R01 · FY2008 · HL · contact PI
Asthma and Nocturnal Hypoxemia in Sickle Cell Anemia$1,894,590
R01 · FY2007 · HL · contact PI
Silent Cerebral Infarct Multi-Center Clinical Trial$1,026,745
U01 · FY2007 · NS · contact PI
ASTHMA AND NOCTURNAL HYPOXEMIA IN SICKLE CELL ANEMIA$7,456
M01 · FY2007 · RR · contact PI
Asthma and Nocturnal Hypoxemia in Sickle Cell Anemia$2,047,637
R01 · FY2006 · HL · contact PI
Silent Cerebral Infarct Multi-Center Clinical Trial$1,419,782
U01 · FY2006 · NS · contact PI
Increasing Blood and Cord Blood Donation in Blacks$191,502
R01 · FY2006 · DK · contact PI
SCREENING AND TREATMENT OF SILENT INFARCTS FOR CHILDREN WITH SICKLE CELL DISE$1,666
M01 · FY2006 · RR · contact PI
IMPORTANCE OF HEMODYNAMIC FACTORS IN THE PROGNOSIS OF STROKE IN PATIENT WITH SCD$833
M01 · FY2006 · RR · contact PI
IMPORTANCE OF HEMODYNAMIC FACTORS IN THE PROGNOSIS OF STROKE IN SICKLE CELL$416
M01 · FY2006 · RR · contact PI
Silent Cerebral Infarct Multi-Center Clinical Trial$1,893,257
U01 · FY2005 · NS
Asthma and Nocturnal Hypoxemia in Sickle Cell Anemia$1,870,976
R01 · FY2005 · HL
Increasing Blood and Cord Blood Donation in Blacks$196,110
R01 · FY2005 · DK
FEASIBILITY, SAFETY AND SHORT-TERM EFFICACY OF PROLONGED GANCICLOVIR PROPHYLAXIS$3,697
M01 · FY2005 · RR
IMPORTANCE OF HEMODYNAMIC FACTORS IN THE PROGNOSIS OF STROKE IN PATIENT WITH SCD$3,287
M01 · FY2005 · RR
SCREENING AND TREATMENT OF SILENT INFARCTS FOR CHILDREN WITH SICKLE CELL DISE$822
M01 · FY2005 · RR
IMPORTANCE OF HEMODYNAMIC FACTORS IN THE PROGNOSIS OF STROKE IN SICKLE CELL$410
M01 · FY2005 · RR
Increasing Blood and Cord Blood Donation in Blacks$196,110
R01 · FY2004 · DK
Feasibility, Safety and Short-Term Efficacy of Prolonged Ganciclovir Prophylaxis$40,880
M01 · FY2004 · RR
Silent Cerebral Infarct Multi-Center Clinical Trial$4,997,543
U01 · FY2003 · NS
Increasing Blood and Cord Blood Donation in Blacks$196,110
R01 · FY2003 · DK
Increasing Blood and Cord Blood Donation in Blacks$222,610
R01 · FY2002 · DK